Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

6-9 November, 2018
Postillion Convention Center,
Amsterdam, Netherlands

Improve delivery and drive products to market through expert insight, new data and technology for oligonucleotide therapeutics

New topics and industry case studies for 2018 focused on:

  • Messenger RNA Therapeutics
  • CRISPR-Cas9 and Applications of Genome Editing
  • Risk-based Approaches to CMC Development of Therapeutics Oligonucleotides
  • Opportunities for Extending to Larger Disease Populations
  • Stereochemical Control of Antisense Oligonucleotides Enhances Target Efficacy
  • Mechanisms of Action and Quantification of Biodistribution of Oligonucleotides
  • Alternative Manufacturing Technologies to Reduce Cost of Goods in Oligonucleotide Manufacturing: Application of Enzymatic Manufacturing
  • Late Stage Drug Product Development and Drug Product Manufacturing
  • Nonclinical Case Studies in Oligonucleotide Development
  • Regulatory Authority Expectations

Gain the Science, Technologies and Contacts You Need to Accelerate Peptide Therapeutics to Market

300+
OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES
40+
CASE STUDIES AND NEW DATA PRESENTATIONS
30+
LEADING EXHIBITORS

Thank you to our EuroTIDES 2018 Scientific Advisory Board

  • Muthiah (Mano) Manoharan, Senior VP, Drug Discovery, Alnylam Pharmaceuticals, Inc, USA
  • Yogesh Sanghvi, President, Rasayan, USA
  • Troels Koch, VP & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen A/S, Denmark
  • Thomas Rupp, Owner, Thomas Rupp Consulting, Germany
  • Professor Cy Stein, Department of Medical Oncology and Experimental Therapeutics, City of Hope Medical Center, USA
  • Mike Gait, MRC Programme Leader, MRC Laboratory of Molecular Biology, UK
  • Dmitry Samarsky, Oligonucleotide (RNAi) Technology and Therapeutics, Experienced Executive and Industry Expert

PARTNERING OPPORTUNITIES FOR EUROTIDES 2018


Highlight your company's expertise to 300+ scientists and key decision makers working across peptide & oligonucleotide development.  For pricing and package options, or to request the latest attendee list, please contact:

Perri Lucatello

Perri.Lucatello@knect365.com | +44 (20) 7017 7247


Linda Cole

Linda.Cole@knect365.com | +44 (20) 7017 6631